Several vaccines, including influenza, hepatitis B, HPV, and most recently, SARS-CoV-2, have been implicated in the onset of MG, often presenting with ocular, bulbar, or facial weakness that improves with acetylcholinesterase inhibitors and immunomodulatory therapies [17-20]. The gene discussed is ACHE; the disease is myasthenia gravis.